<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9080">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05705648</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00109795</org_study_id>
    <nct_id>NCT05705648</nct_id>
  </id_info>
  <brief_title>Nutritional Management of Post COVID-19 Cognitive Symptoms</brief_title>
  <official_title>Nutritional Management of Post COVID-19 Cognitive Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to learn about in brain &quot;fog&quot; complaints associated with&#xD;
      long-COVID in people aged 22-50-years. The main questions it aims to answer are:&#xD;
&#xD;
        -  the natural course of brain &quot;fog&quot; complaints&#xD;
&#xD;
        -  the effect, if any of supplemental dietary oil on brain &quot;fog&quot; complaints Participants&#xD;
           will be asked to undergo some brain testing (X-rays and questions. Treatments they'll be&#xD;
           given will be one of two supplemental oils to consume daily.&#xD;
&#xD;
      Researchers will compare outcomes in the two different oil groups to see if it has any effect&#xD;
      on brain &quot;fog&quot; complaints.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized placebo-control clinical trial comparing two types of nutritional oil and&#xD;
      evaluating the impact, if any, on subjective complaints of long-COVID cognitive changes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 4, 2023</start_date>
  <completion_date type="Anticipated">March 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised placebo-controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind, placebo control</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cognigram(R)</measure>
    <time_frame>12-months</time_frame>
    <description>computer-based cognitive test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment</measure>
    <time_frame>12-months</time_frame>
    <description>Cognitive test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Long COVID</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium chain triglyceride oil 15ml tid x 5 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Safflower oil 15mls tid x 5 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>medium chain triglyceride oil</intervention_name>
    <description>Medium chain triglyceride oil</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Safflower oil</intervention_name>
    <description>Safflower oil</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  confirmed COVID infection, at least 3 months previously, with ongoing cognitive&#xD;
             complaints&#xD;
&#xD;
          -  all other medical conditions stable, and on stable doses of medications (if required)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  COVID infection not confirmed by PCR or Rapid test&#xD;
&#xD;
          -  unable to speak English&#xD;
&#xD;
          -  pre-COVID cognitve complaints, and/or medical diagnoses affecting cognitive function&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>January 27, 2023</study_first_submitted>
  <study_first_submitted_qc>January 27, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2023</study_first_posted>
  <last_update_submitted>May 22, 2023</last_update_submitted>
  <last_update_submitted_qc>May 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>brain fog; confusion; memory loss; functional decline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Post-Acute COVID-19 Syndrome</mesh_term>
    <mesh_term>Neurobehavioral Manifestations</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

